MARCH9 Double Nickase Plasmid (h): sc-410240-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MARCH9 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- MARCH9 Double Nickase Plasmid (h) and MARCH9 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting MARCH9. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MARCH9 Double Nickase Plasmid (h) | sc-410240-NIC | 20 µg | $410.00 | |||
MARCH9 Double Nickase Plasmid (h2) | sc-410240-NIC-2 | 20 µg | $410.00 |
MARCH9 encodes a membrane-associated RING-CH E3 ubiquitin ligase that localizes to endomembrane compartments and regulates protein turnover through ubiquitin-dependent sorting and degradation. By catalyzing ubiquitination of select membrane proteins, MARCH9 contributes to endocytic trafficking, lysosomal targeting, and quality control processes that shape receptor availability and intracellular signaling dynamics. These activities link MARCH9 to pathways governing immune-related membrane protein regulation and cellular homeostasis, where altered ubiquitin ligase function can influence stress responses and remodeling of the cell surface proteome. Dysregulation of membrane protein ubiquitination and trafficking is relevant to mechanistic studies of immune signaling, infection-associated host responses, and broader proteostasis disturbances observed across diverse disease contexts.
MARCH9 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the MARCH9 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within MARCH9. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt MARCH9 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of MARCH9-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.